University Of California San Francisco

As the COVID-19 pandemic intensifies across the United States, incidence among individuals with cancer remains relatively low.

ORLANDO — LentiGlobin gene therapy led to substantial reductions of sickle hemoglobin and considerable improvement in key markers of hemolysis, according to updated results from the phase 1/phase 2 HGB-206 study presented at TCT | Transplantation & Cellular Therapy Meetings.

Data indicate that fewer medical students and fellows are joining the HIV workforce, perhaps under the impression that HIV is no longer the exciting and rewarding field it once was. We asked Peter Chin-Hong, MD, professor of medicine and director of the transplant infectious disease program at University of California, San Francisco (UCSF), what the “new HIV” is — the ID-related field that is attracting today’s young clinicians.

Fewer medical trainees are entering the field of HIV, leaving a shortage in the workforce that is likely to get worse, experts said. The trend coincides with slowed progress in reducing new infections, and likely complicates a lofty new federal plan to end the U.S. epidemic in 10 years.

A study published in the Journal of the American Heart Association in June 2019 concluding that patients who smoked electronic cigarettes every day or some days had an increased risk for MI was retracted on Feb. 18, 2020.

Cytovia Therapeutics announced research partnerships with both The New York Stem Cell Foundation Research Institute and University of California, San Francisco, for the development of induced pluripotent stem cell-derived chimeric antigen receptor-natural killer cell therapies for cancer.

SAN ANTONIO — Residual cancer burden after neoadjuvant chemotherapy accurately predicted long-term recurrence risk and survival across all breast cancer subtypes, according to results of a meta-analysis presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Ado-trastuzumab emtansine extended DFS compared with paclitaxel plus trastuzumab among patients with early-stage HER2-positive breast cancer, according to results of the randomized phase 2 ATEMPT trial presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Margetuximab plus chemotherapy conferred a numerically small but statistically significant PFS and OS compared with trastuzumab plus chemotherapy for patients with relapsed or refractory HER2-positive metastatic breast cancer, according to results of a second interim analysis of the randomized phase 3 SOPHIA trial presented at San Antonio Breast Cancer Symposium.

SAN FRANCISCO — Prevymis safely resolved inflammation among patients with cytomegalovirus-associated uveitis, according to a presentation at the American Academy of Ophthalmology annual meeting.